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-Trace Protein
Versus Cystatin C
Which Is a Better Surrogate Marker
of Renal Function Versus Prognostic
Indicator in Cardiovascular Diseases?*
Horng H. Chen, MB, BCH
Rochester, Minnesota
-trace protein (BTP), also known as prostaglandin D2
synthase, is a low-molecular-weight glycoprotein (25.2
kDa) that was initially isolated from cerebrospinal fluid and
served as a marker of cerebrospinal fluid leakage (1). It is
expressed in all tissues except the ovaries, with biological
actions that include vasodilatation, bronchoconstriction,
inhibition of platelet aggregation, and recruitment of in-
flammatory cells. BTP was also found to be increased in the
serum of patients with renal failure. The half-life of BTP is
approximately 1.2 h, and it is freely filtered through the
glomerular basement membrane with minimal nonrenal
elimination. Hence, it has been proposed as a new endog-
enous marker of glomerular filtration rate (GFR). Studies
have confirmed a good correlation between serum BTP
levels and the GFR measurement based on inulin clearance
and nuclear medicine methods (1).
See page 849
Cystatin C (cys-C) is a 122-amino acid, 13-kDa protein
that is a member of a family of competitive inhibitors of
cysteine proteases. cys-C is produced by all human nucle-
ated cells, and the human cys-C gene is of the housekeeping
type, which indicates a stable production rate of cys-C by
most nucleated cell types. cys-C has several properties that
make it a good candidate marker of GFR, including a
constant production rate, free filtration at the glomerulus,
complete reabsorption and catabolism by the proximal
tubules with no reabsorption into the bloodstream, and no
renal tubular secretion (2).
*Editorials published in the Journal of the American College of Cardiology reflect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
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eported that in a cohort of 220 patients hospitalized with
cute decompensated heart failure, BTP and cys-C pre-
icted risk for death and/or heart failure hospitalization and
ere superior to standard measures of renal function for this
ndication. Plasma BTP concentration was positively corre-
ated with cys-C concentration. Both, plasma BTP and
ys-C concentrations, were positively correlated with serum
reatinine, blood urea nitrogen, age, New York Heart
ssociation functional class, N-terminal pro–B-type natri-
retic peptide, uric acid, troponin T, and C-reactive protein,
hereas both were negatively correlated with estimated
lomerular filtration rate (eGFR), serum albumin, and
emoglobin. Surprisingly, neither BTP nor cys-C was
ssociated with worsening renal function during index
ospitalization. After multivariable adjustment, both BTP
nd cys-C were significant predictors of death/heart failure
ospitalization, whereas serum creatinine, eGFR, and blood
rea nitrogen were no longer significant. Importantly, in
atients with eGFR 60 ml/min, elevated concentrations
f BTP and cys-C were still associated with significantly
igher risk of adverse clinical events. Net reclassification
ndex analysis suggested that BTP and cys-C had compa-
able information regarding prognosis.
s BTP a better surrogate marker of renal function as
ompared with cys-C? In an elegant study by Donadio et
l. (4), the authors evaluated the relationship between serum
evels of BTP and GFR for comparison with cys-C. Serum
evels of BTP progressively increased with the reduction of
FR. A good correlation was found between GFR and
erum levels of BTP (r  0.918) and cys-C (r  0.937).
mportantly, no statistically significant difference was found
etween BTP and cys-C as indicators of a moderate GFR
mpairment. As a tool for GFR measurement, BTP may
ave some distinct advantages. It has been reported that
erum BTP levels do not have a significant relationship with
-reactive protein and that they are unaffected by body
omposition. During the third trimester of pregnancy, BTP,
ut not cys-C, has been shown to adequately reflect the
FR. Unlike cys-C, thyroid function has not been reported
o affect the concentration of BTP. Another possible ad-
antage would be the lack of effect of corticosteroid admin-
stration on BTP concentrations. However, Abbink et al.
5) demonstrated that glucocorticoid therapy resulted in a
ose-dependent underestimation of GFR by serum cys-C
nd an overestimation by BTP. Hence, BTP offers no
dvantage over cys-C in this setting. The Mild and Mod-
rate Kidney Disease Study Group evaluated measured
FR and the serum markers cys-C and BTP for diagnostic
ccuracy in defining stage of kidney impairment and as risk
redictors of chronic kidney disease (CKD) progression (1).
hey measured serum marker concentrations in 227 pa-
ients with primary nondiabetic CKD and various degrees of
enal impairment and followed 177 patients prospectively
or up to 7 years to assess progression of CKD. At baseline,
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-Trace Protein and Cardiovascular Diseases February 15, 2011:859–60cys-C and BTP were strongly correlated with GFR as
measured by iohexol clearance. Sixty-five patients experi-
enced progression of CKD, defined as doubling of baseline
creatinine and/or terminal renal failure during prospective
follow-up. These patients were older and had a lower GFR
and higher cys-C and BTP values at baseline as compared
with the patients who did not reach a predefined renal end
point. Cox proportional hazards regression analysis revealed
that both BTP and cys-C were equally strong predictors of
CKD progression, even after adjustment for age, sex, GFR,
and proteinuria.
Is BTP a better prognostic marker as compared with
cys-C? Several cohort and population-based studies have
emonstrated that cys-C is an important prognostic indi-
ator of cardiovascular and overall mortality (6). In compar-
son, the prognostic value of BTP in cardiovascular disease
s less defined. Hirawa et al. (7) demonstrated that serum
nd urinary levels of BTP were increased in essential
ypertension, even with normal renal function. The increase
n serum BTP was affected by blood pressure, urinary
xcretions of BTP, serum creatinine, and sex. Eguchi et al.
8) demostrated that BTP is present in both endocardium
nd myocardium of normal subjects and at the stenotic site
f patients with stable angina and is secreted into the
oronary circulation. Immunoreactivity and mRNA expres-
ion of BTP confirm that BTP was definitely localized and
enerated in atherosclerotic plaques, especially of the human
oronary artery (9). Furthermore, BTP was also found in
ascular endothelial cells in the systemic atherosclerotic
rtery. Hence, these findings suggest that BTP may play a
ole in the pathophysiology for cardiovascular diseases and
ay therefore have prognostic value beyond being a surro-
ate marker of renal function. Manzano-Ferna´ndez et al. (3)
eported that using receiver-operator characteristic analyses,
he prognostic accuracy of BTP in predicting adverse
linical events survival in acute decompensated heart failure
as slightly superior to the more conventional measures of
enal function and was comparable to cys-C. pFuture research directions. Although the current evidence
suggests that BTP is comparable to cys-C as a surrogate
marker of renal function, more studies are needed to define
the prognostic value of BTP in various cardiovascular
diseases such as coronary artery diseases, hypertension,
diabetes, and so on. It would be very clinically relevant to
determine whether serial measurements of BTP have added
prognostic value.
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